Fresenius Medical Care (NYSE:FMS) Reaches New 12-Month High – Time to Buy?

Fresenius Medical Care AG (NYSE:FMS)’s stock price reached a new 52-week high during trading on Friday . The stock traded as high as $25.96 and last traded at $25.67, with a volume of 474236 shares trading hands. The stock had previously closed at $24.73.

Analyst Ratings Changes

FMS has been the topic of a number of research analyst reports. StockNews.com upgraded Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. Truist Financial upped their price objective on Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a research note on Monday, January 6th.

Fresenius Medical Care Price Performance

The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. The business’s fifty day moving average is $24.14 and its 200 day moving average is $22.67. The company has a market cap of $14.05 billion, a P/E ratio of 19.79, a PEG ratio of 0.76 and a beta of 0.93.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Callan Family Office LLC bought a new stake in Fresenius Medical Care in the 4th quarter valued at about $502,000. Callan Capital LLC purchased a new stake in shares of Fresenius Medical Care during the 4th quarter valued at approximately $297,000. Sanctuary Advisors LLC bought a new position in Fresenius Medical Care in the 4th quarter worth approximately $983,000. ABC Arbitrage SA purchased a new position in Fresenius Medical Care in the 4th quarter valued at approximately $4,215,000. Finally, Verition Fund Management LLC bought a new stake in Fresenius Medical Care during the 3rd quarter valued at $237,000. Hedge funds and other institutional investors own 8.37% of the company’s stock.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.